docetaxel anhydrous has been researched along with ketoconazole in 33 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (ketoconazole) | Trials (ketoconazole) | Recent Studies (post-2010) (ketoconazole) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 6,202 | 706 | 1,269 |
| 12,110 | 3,216 | 6,920 | 149 | 0 | 120 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | ketoconazole (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 1 | Homo sapiens (human) | 2.6 | |
| 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial | Homo sapiens (human) | 0.34 | |
| 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial | Mus musculus (house mouse) | 0.36 | |
| Bile salt export pump | Homo sapiens (human) | 3.44 | |
| Steroid 17-alpha-hydroxylase/17,20 lyase | Homo sapiens (human) | 1.5811 | |
| ATP-dependent translocase ABCB1 | Mus musculus (house mouse) | 6.7 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 4.6771 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.2303 | |
| Steroid 21-hydroxylase | Homo sapiens (human) | 6.655 | |
| Cytochrome P450 2C8 | Homo sapiens (human) | 0.06 | |
| Aromatase | Homo sapiens (human) | 1.4111 | |
| Steroid 17-alpha-hydroxylase/17,20 lyase | Rattus norvegicus (Norway rat) | 2.0802 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 5.425 | |
| Cholesterol side-chain cleavage enzyme, mitochondrial | Rattus norvegicus (Norway rat) | 3.32 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 1.067 | |
| Cytochrome P450 2A2 | Rattus norvegicus (Norway rat) | 0.456 | |
| Cytochrome P450 11B1, mitochondrial | Bos taurus (cattle) | 0.38 | |
| Cytochrome P450 11B1, mitochondrial | Homo sapiens (human) | 0.4519 | |
| Translocator protein | Rattus norvegicus (Norway rat) | 3.76 | |
| Cytochrome P450 7A1 | Rattus norvegicus (Norway rat) | 1.2975 | |
| Cytochrome P450 11B2, mitochondrial | Homo sapiens (human) | 0.5179 | |
| ATP-dependent translocase ABCB1 | Mus musculus (house mouse) | 3.8 | |
| Thromboxane-A synthase | Homo sapiens (human) | 2.165 | |
| Gonadotropin-releasing hormone receptor | Rattus norvegicus (Norway rat) | 2 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.531 | |
| Type-1 angiotensin II receptor | Oryctolagus cuniculus (rabbit) | 0.0078 | |
| Cytochrome P450 4F2 | Homo sapiens (human) | 1.6 | |
| 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial | Homo sapiens (human) | 0.4144 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1.9036 | |
| Lanosterol 14-alpha demethylase | Homo sapiens (human) | 0.19 | |
| Cytochrome P450 7A1 | Mus musculus (house mouse) | 1.2975 | |
| Lanosterol 14-alpha demethylase | Rattus norvegicus (Norway rat) | 0.083 | |
| Epoxide hydrolase 1 | Homo sapiens (human) | 0.04 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 2.774 | |
| Cytochrome P450 3A5 | Homo sapiens (human) | 0.2535 | |
| Bifunctional epoxide hydrolase 2 | Homo sapiens (human) | 0.04 | |
| Sterol 14-alpha demethylase | Trypanosoma cruzi strain CL Brener | 0.014 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (33.33) | 29.6817 |
| 2010's | 19 (57.58) | 24.3611 |
| 2020's | 3 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Aggarwal, A; Baranda, J; Reed, G; Van Veldhuizen, PJ; Williamson, S; Zulfiqar, M | 1 |
| Arlen, PM; Cox, MC; Dahut, W; Figg, WD; Gulley, J; Linehan, WM | 1 |
| Baker, SD; Engels, FK; Lee, CK; Loos, WJ; Sparreboom, A; Ten Tije, AJ; Verweij, J; Vulto, AG | 1 |
| George, DJ; Gilligan, TD; Hagmann, E; Jacobson, JO; Kantoff, PW; Kaufman, DS; Manola, J; Oh, WK; Smith, MR | 1 |
| Fan, L; Goh, BC; Lee, HS; Lee, SC; Ong, AB; Soo, R; Sukri, N; Tham, LS; Wang, L; Yong, WP | 1 |
| Engels, FK; Loos, WJ; Mathot, RA; van Schaik, RH; Verweij, J | 2 |
| Hu, XL; Huang, Q; Lu, YH; Sun, JG; Wang, GJ; Zhang, Q | 1 |
| Goh, BC; Lee, HS; Lee, SC; Soo, R; Sukri, N; Tham, LS; Wang, LZ; Wong, CI; Yong, WP | 1 |
| Bamias, A; Dimopoulos, MA; Gerassimos, A; Harilaos, K; Ioannis, V; Iraklis, M; Konstantinos, L; Lainakis, G; Michael, C; Nikos, A | 1 |
| Berry, W; Fleming, M; Galsky, MD; Hutson, TE; Kondagunta, GV; Simon, K; Sonpavde, G | 1 |
| Ajiboye, AS; Arlen, PM; Chen, X; Dahut, WL; Figg, WD; Gulley, JL; Parnes, HL; Price, DK; Steinberg, SM; Woo, S; Wright, JJ; Zhu, W | 1 |
| Buhari, SA; Chan, CW; Chuah, BYS; Cordero, MT; Goh, BC; Iau, P; Lee, SC; Lim, SE; Lim, YW; Soo, R; Sukri, NB; Tan, SH; Wang, LZ | 1 |
| Ahmed, FJ; Diwan, PV; Parikh, N; Sistla, R; Venishetty, VK | 1 |
| Miller, K | 1 |
| Holzbeierlein, JM; Nisbet, AA; Reed, GA; Thrasher, JB; VanVeldhuizen, PJ; Womble, PR | 1 |
| Agarwal, N | 1 |
| Diwan, PV; Komuravelli, R; Kuncha, M; Sistla, R; Venishetty, VK | 1 |
| Kim, W; Ryan, CJ | 1 |
| Armstrong, AJ; Galsky, MD; Leopold, L; Pond, GR; Sonpavde, G; Wood, BA | 1 |
| Arévalo, E; Carranza, OE; Castañón, E; Castillo, A; Collado-Gómez, V; Fusco, JP; Gil-Aldea, I; Gil-Bazo, I; López, I; Zudaire, ME | 1 |
| Amato, RJ; Saxena, S; Stepankiw, M | 1 |
| Aggarwal, R; Carducci, M; George, D; Halabi, S; Kantoff, P; Kelly, WK; Mahoney, JF; Millard, F; Monk, JP; Morris, MJ; Small, EJ; Stadler, WM | 1 |
| Berger, R; Carducci, MA; Eisenberger, MA; Gottfried, M; Keizman, D; Leibowitz-Amit, R; Peer, A; Sella, A; Sinibaldi, V | 1 |
| Chang, CY; Deeken, JF; Desai, N; Johnson, MD; Rudek, MA; Steadman, K | 1 |
| Beckett, LA; Lara, PN; Lo, EN; Pan, CX; Robles, D; Sands, JM; Suga, JM | 1 |
| Antonarakis, ES; Denmeade, SR; Luber, B; Teply, BA | 1 |
| Pramod, SV; Safriadi, F; Tresnanda, RI | 1 |
| Burns, J; Caram, MEV; Hollenbeck, BK; Kumbier, K; Shahinian, V; Skolarus, TA; Sparks, JB; Stensland, KD; Tsao, PA; Washington, SL | 1 |
| Beloglazkina, EK; Ber, AP; Borisova, YA; Chepikova, OE; Erofeev, A; Gorelkin, P; Khazanova, ES; Khudyakov, AD; Kolmogorov, VS; Kovalev, S; Machulkin, AE; Majouga, AG; Nimenko, EA; Pankratov, AA; Petrov, SA; Plotnikova, EA; Pokrovsky, VS; Polshakov, VI; Shafikov, RR; Skvortsov, DA; Smirnova, GB; Uspenskaya, AA; Vaneev, AN; Zamyatnin, AA; Zyk, NU; Zyk, NV | 1 |
4 review(s) available for docetaxel anhydrous and ketoconazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Castration resistant prostate cancer 2011].
Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Humans; Ketoconazole; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Taxoids; Tissue Extracts | 2011 |
Androgen receptor directed therapies in castration-resistant metastatic prostate cancer.
Topics: Androgen Receptor Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Docetaxel; Drug Resistance, Neoplasm; Humans; Ketoconazole; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Taxoids; Thiohydantoins | 2012 |
Ketoconazole for the Treatment of Docetaxel-Naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Systematic Review.
Topics: Adrenal Cortex Hormones; Antifungal Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Hydrocortisone; Ketoconazole; Male; Prednisolone; Prednisone; Progression-Free Survival; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Retrospective Studies | 2021 |
12 trial(s) available for docetaxel anhydrous and ketoconazole
| Article | Year |
|---|---|
Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma: a phase I and pharmacokinetic study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Humans; Ketoconazole; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2003 |
Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel.
Topics: Administration, Oral; Adult; Antifungal Agents; Antineoplastic Agents, Phytogenic; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Docetaxel; Drug Administration Schedule; Drug Interactions; Enzyme Inhibitors; Female; Humans; Ketoconazole; Male; Middle Aged; Taxoids | 2004 |
A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Estramustine; Humans; Ketoconazole; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome | 2005 |
Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug.
Topics: Administration, Oral; Anesthetics, Intravenous; Antifungal Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Docetaxel; Female; Half-Life; Humans; Infusions, Intravenous; Isoenzymes; Ketoconazole; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Taxoids | 2006 |
Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme System; Docetaxel; Female; Humans; Ketoconazole; Male; Middle Aged; Neoplasms; Polymorphism, Single Nucleotide; Taxoids | 2006 |
A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers.
Topics: Antineoplastic Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Docetaxel; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Ketoconazole; Male; Maximum Tolerated Dose; Midazolam; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neutropenia; Taxoids | 2008 |
A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Docetaxel; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Humans; Ketoconazole; Male; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids; Treatment Failure | 2010 |
Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Docetaxel; Drug Therapy, Combination; Female; Humans; Ketoconazole; Maximum Tolerated Dose; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2010 |
A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients.
Topics: Aged; Antineoplastic Agents; Docetaxel; Drug Therapy, Combination; Humans; Ketoconazole; Male; Middle Aged; Neoadjuvant Therapy; Preoperative Care; Prostatectomy; Prostatic Neoplasms; Risk Factors; Taxoids | 2011 |
Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Gossypol; Humans; Ketoconazole; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Prednisone; Proportional Hazards Models; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2013 |
Phase II trial assessing granulocyte-macrophage-colony stimulating factor, ketoconazole plus mitoxantrone in metastatic castration-resistant prostate cancer progressing after docetaxel treatments.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Ketoconazole; Male; Middle Aged; Mitoxantrone; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2013 |
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (
Topics: Aged; Androgen Antagonists; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Drug Therapy, Combination; Follow-Up Studies; Humans; International Agencies; Ketoconazole; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Orchiectomy; Prednisone; Prognosis; Prostatic Neoplasms; Retrospective Studies; Survival Rate; Taxoids | 2013 |
17 other study(ies) available for docetaxel anhydrous and ketoconazole
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
National Cancer Institute intramural approach to advanced prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomedical Research; Cancer Vaccines; Clinical Trials as Topic; Docetaxel; Humans; Ketoconazole; Male; National Institutes of Health (U.S.); Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Thalidomide; United States | 2002 |
Influence of ketoconazole on the fecal and urinary disposition of docetaxel.
Topics: Administration, Oral; Adult; Aged; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Docetaxel; Feces; Female; Humans; Ketoconazole; Male; Middle Aged; Neoplasms; Taxoids; Tritium | 2007 |
Simultaneous determination of docetaxel and ketoconazole in rat plasma by liquid chromatography/electrospray ionization tandem mass spectrometry.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Chemical Analysis; Chromatography, High Pressure Liquid; Complex Mixtures; Docetaxel; Ketoconazole; Rats; Spectrometry, Mass, Electrospray Ionization; Taxoids | 2007 |
Biweekly doxorubicin/ketoconazole as second-line treatment in docetaxel-resistant, hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antifungal Agents; Antineoplastic Agents; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Therapy, Combination; Follow-Up Studies; Humans; Ketoconazole; Male; Middle Aged; Prostatic Neoplasms; Taxoids | 2008 |
Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer.
Topics: Aged; Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Humans; Ketoconazole; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids; Time Factors; Treatment Outcome | 2009 |
Application of validated RP-HPLC method for simultaneous determination of docetaxel and ketoconazole in solid lipid nanoparticles.
Topics: Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Docetaxel; Drug Delivery Systems; Drug Stability; Ketoconazole; Least-Squares Analysis; Lipids; Nanoparticles; Reproducibility of Results; Sensitivity and Specificity; Taxoids | 2011 |
Editorial comment.
Topics: Antineoplastic Agents; Docetaxel; Humans; Ketoconazole; Male; Prostatic Neoplasms; Taxoids | 2011 |
Increased brain uptake of docetaxel and ketoconazole loaded folate-grafted solid lipid nanoparticles.
Topics: Animals; Brain; Cell Line; Docetaxel; Folic Acid; Ketoconazole; Lipids; Nanoparticles; Particle Size; Rats; Rats, Wistar; Taxoids | 2013 |
Safety and efficacy of maintenance therapy with a nonspecific cytochrome P17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castration-resistant prostate cancer.
Topics: 14-alpha Demethylase Inhibitors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Ketoconazole; Maintenance Chemotherapy; Male; Middle Aged; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase; Taxoids; Treatment Outcome | 2013 |
Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Combined Modality Therapy; Databases, Factual; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Ketoconazole; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Retreatment; Retrospective Studies; Taxoids; Treatment Outcome | 2014 |
Combination antiretroviral therapy (cART) component ritonavir significantly alters docetaxel exposure.
Topics: Alkynes; Animals; Antineoplastic Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dexamethasone; Docetaxel; Drug Interactions; Drug Therapy, Combination; Enzyme Induction; HIV Protease Inhibitors; Ketoconazole; Liver; Male; Mice; Reverse Transcriptase Inhibitors; Ritonavir; Taxoids | 2014 |
Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Hydrocortisone; Ketoconazole; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2015 |
Singapore Cancer Network (SCAN) Guidelines for the Management of Advanced Castrate-Resistant Prostate Cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Cancer Vaccines; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Ketoconazole; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Singapore; Taxoids; Tissue Extracts | 2015 |
The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Ketoconazole; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Differential adoption of castration-resistant prostate cancer treatment across facilities in a national healthcare system.
Topics: Delivery of Health Care; Docetaxel; Humans; Ketoconazole; Male; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2023 |
Synthesis, Characterization, and Preclinical Evaluation of a Small-Molecule Prostate-Specific Membrane Antigen-Targeted Monomethyl Auristatin E Conjugate.
Topics: Antigens, Surface; Cell Line, Tumor; Coordination Complexes; Glutamate Carboxypeptidase II; Humans; Male; Microsomes, Liver; Oligopeptides; Prostatic Neoplasms; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2021 |